Literature DB >> 34859882

Comparative pathology, molecular pathogenicity, immunological features, and genetic characterization of three highly pathogenic human coronaviruses (MERS-CoV, SARS-CoV, and SARS-CoV-2).

A A Rabaan1, A A Mutair, Z A Alawi, S Alhumaid, M A Mohaini, J Aldali, R Tirupathi, A A Sule, T Koritala, R Adhikari, M Bilal, M Dhawan, R K Mohapatra, R Tiwari, S A Sami, S Mitra, M K Pandey, H Harapan, T B Emran, K Dhama.   

Abstract

The last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The COVID-19 pandemic has resulted in an unprecedented crisis with devastating socio-economic and health impacts worldwide. This highlights the fact that CoVs continue to evolve and have the genetic flexibility to become highly pathogenic in humans and other mammals. SARS-CoV-2 carries a high genetic homology to the previously identified CoV (SARS-CoV), and the immunological and pathogenic characteristics of SARS-CoV-2, SARS-CoV, and MERS contain key similarities and differences that can guide therapy and management. This review presents salient and updated information on comparative pathology, molecular pathogenicity, immunological features, and genetic characterization of SARS-CoV, MERS-CoV, and SARS-CoV-2; this can help in the design of more effective vaccines and therapeutics for countering these pathogenic CoVs.

Entities:  

Mesh:

Year:  2021        PMID: 34859882     DOI: 10.26355/eurrev_202111_27270

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  3 in total

Review 1.  MicroRNAs in the development of potential therapeutic targets against COVID-19: A narrative review.

Authors:  Jivan Qasim Ahmed; Sazan Qadir Maulud; Manish Dhawan; Om Prakash Choudhary; Paywast Jamal Jalal; Rezhna Kheder Ali; Gahin Abdulraheem Tayib; Dlshad Abdullah Hasan
Journal:  J Infect Public Health       Date:  2022-06-21       Impact factor: 7.537

2.  Acute Pericarditis Secondary to COVID-19 Infection.

Authors:  Arminder Singh; Lam Nguyen; Stephanie Everest; Pinang Shastri; Rahel H Alemu
Journal:  Cureus       Date:  2021-12-26

3.  Coronavirus disease 2019 presenting as psychosis: a case report.

Authors:  Nyanyuie Kodjo Lovi; Selase Kofi Kekrebesi; Mary Osei; Eugene Yeboah
Journal:  J Med Case Rep       Date:  2022-04-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.